Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Precision screening identifies mitoxantrone as a multitarget inhibitor in ageing-associated cancers with extensive computational validation and doxorubicin comparison
by
Pushparaj, Peter Natesan
, Assidi, Mourad
, Almuhammadi, Asma
, Al-Qahtani, Mohammed H.
, Buhmeida, Abdelbaset
, Alganmi, Nofe Ateq
in
Aging
/ Antineoplastic Agents - chemistry
/ Antineoplastic Agents - pharmacology
/ Binding
/ Biology and Life Sciences
/ Cancer
/ Cell proliferation
/ CHK1 protein
/ COVID-19
/ Cytokines
/ Data collection
/ Density functional theory
/ Deoxyribonucleic acid
/ DNA
/ DNA damage
/ DNA repair
/ Doxorubicin
/ Doxorubicin - chemistry
/ Doxorubicin - pharmacology
/ Doxorubicin - therapeutic use
/ Epigenetics
/ Free energy
/ Genomic instability
/ Growth factors
/ Health care
/ Humans
/ Kinases
/ Leukemia
/ Ligands
/ MDM2 protein
/ Medicine and Health Sciences
/ Mitoxantrone
/ Mitoxantrone - chemistry
/ Mitoxantrone - pharmacology
/ Mitoxantrone - therapeutic use
/ Molecular Docking Simulation
/ Mutation
/ Neoplasms - drug therapy
/ Neoplasms - metabolism
/ Oncology
/ Pharmacokinetics
/ Physical Sciences
/ Physiology
/ Poly(ADP-ribose) polymerase
/ Prostate cancer
/ Proteins
/ Research and Analysis Methods
/ Senescence
/ Simulation
/ Telomerase
/ TOR protein
/ Ubiquitin-protein ligase
2026
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Precision screening identifies mitoxantrone as a multitarget inhibitor in ageing-associated cancers with extensive computational validation and doxorubicin comparison
by
Pushparaj, Peter Natesan
, Assidi, Mourad
, Almuhammadi, Asma
, Al-Qahtani, Mohammed H.
, Buhmeida, Abdelbaset
, Alganmi, Nofe Ateq
in
Aging
/ Antineoplastic Agents - chemistry
/ Antineoplastic Agents - pharmacology
/ Binding
/ Biology and Life Sciences
/ Cancer
/ Cell proliferation
/ CHK1 protein
/ COVID-19
/ Cytokines
/ Data collection
/ Density functional theory
/ Deoxyribonucleic acid
/ DNA
/ DNA damage
/ DNA repair
/ Doxorubicin
/ Doxorubicin - chemistry
/ Doxorubicin - pharmacology
/ Doxorubicin - therapeutic use
/ Epigenetics
/ Free energy
/ Genomic instability
/ Growth factors
/ Health care
/ Humans
/ Kinases
/ Leukemia
/ Ligands
/ MDM2 protein
/ Medicine and Health Sciences
/ Mitoxantrone
/ Mitoxantrone - chemistry
/ Mitoxantrone - pharmacology
/ Mitoxantrone - therapeutic use
/ Molecular Docking Simulation
/ Mutation
/ Neoplasms - drug therapy
/ Neoplasms - metabolism
/ Oncology
/ Pharmacokinetics
/ Physical Sciences
/ Physiology
/ Poly(ADP-ribose) polymerase
/ Prostate cancer
/ Proteins
/ Research and Analysis Methods
/ Senescence
/ Simulation
/ Telomerase
/ TOR protein
/ Ubiquitin-protein ligase
2026
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Precision screening identifies mitoxantrone as a multitarget inhibitor in ageing-associated cancers with extensive computational validation and doxorubicin comparison
by
Pushparaj, Peter Natesan
, Assidi, Mourad
, Almuhammadi, Asma
, Al-Qahtani, Mohammed H.
, Buhmeida, Abdelbaset
, Alganmi, Nofe Ateq
in
Aging
/ Antineoplastic Agents - chemistry
/ Antineoplastic Agents - pharmacology
/ Binding
/ Biology and Life Sciences
/ Cancer
/ Cell proliferation
/ CHK1 protein
/ COVID-19
/ Cytokines
/ Data collection
/ Density functional theory
/ Deoxyribonucleic acid
/ DNA
/ DNA damage
/ DNA repair
/ Doxorubicin
/ Doxorubicin - chemistry
/ Doxorubicin - pharmacology
/ Doxorubicin - therapeutic use
/ Epigenetics
/ Free energy
/ Genomic instability
/ Growth factors
/ Health care
/ Humans
/ Kinases
/ Leukemia
/ Ligands
/ MDM2 protein
/ Medicine and Health Sciences
/ Mitoxantrone
/ Mitoxantrone - chemistry
/ Mitoxantrone - pharmacology
/ Mitoxantrone - therapeutic use
/ Molecular Docking Simulation
/ Mutation
/ Neoplasms - drug therapy
/ Neoplasms - metabolism
/ Oncology
/ Pharmacokinetics
/ Physical Sciences
/ Physiology
/ Poly(ADP-ribose) polymerase
/ Prostate cancer
/ Proteins
/ Research and Analysis Methods
/ Senescence
/ Simulation
/ Telomerase
/ TOR protein
/ Ubiquitin-protein ligase
2026
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Precision screening identifies mitoxantrone as a multitarget inhibitor in ageing-associated cancers with extensive computational validation and doxorubicin comparison
Journal Article
Precision screening identifies mitoxantrone as a multitarget inhibitor in ageing-associated cancers with extensive computational validation and doxorubicin comparison
2026
Request Book From Autostore
and Choose the Collection Method
Overview
Ageing-associated cancers are characterised by the dual hallmarks of persistent DNA damage and the ability of tumour cells to escape senescence checkpoints, which drive genomic instability and uncontrolled proliferation. In this study, we identified crucial proteins with PDB IDs—2YEX (Chk1 kinase), 4HG7 (MDM2 E3 ubiquitin ligase), 4JSX (mTOR kinase domain), and 5DS3 (PARP-1 DNA repair enzyme)—involved in ageing-related cancers and performed docking studies with Extra Precision (XP) followed by MM-GBSA-based pose processing against the FDA-approved DrugBank library (LigPrep: 10907 compounds). The extensive docking computations identified many good candidates; however, Mitoxantrone emerges as the topmost candidate with docking scores of −6.23 to −16.044 Kcal/mol and MM-GBSA score of −49.19 to −85.14 Kcal/mol, which currently is being used to treat advanced prostate cancer and acute nonlymphocytic leukaemia (ANLL) and would be easier to repurpose to other ageing-related cancers. Mitoxantrone also emerges as a better candidate compared to the control drug Doxorubicin. Further, the complex of all 4 proteins with Mitoxantrone was taken for interaction fingerprints and found that the most interacting residues with counts were 6GLY, 6VAL, 5GLU, 5LEU, 4ALA, 3ASP, and 3TYR, among others. The pharmacokinetics and Density Functional Theory computations further support Mitoxantrone as a potential candidate. We also performed a 5-nanoseconds (ns) WaterMap for hydration site identification and the role of water in stabilisation of the complex, followed by a 100 ns MD Simulation that resulted in stable deviation and fluctuations mostly under <2Å and a web of simulation interactions making the complex stable. Furthermore, the same trajectories were used for the Binding Free and Total Complex Energies computations, revealing that the complexes were stable. All the studies, from protein energies to docking to simulation and binding free energy, supported the stable complexes; however, experimental studies are necessary before their use.
Publisher
Public Library of Science,PLOS,Public Library of Science (PLoS)
Subject
/ Antineoplastic Agents - chemistry
/ Antineoplastic Agents - pharmacology
/ Binding
/ Cancer
/ COVID-19
/ DNA
/ Doxorubicin - therapeutic use
/ Humans
/ Kinases
/ Leukemia
/ Ligands
/ Medicine and Health Sciences
/ Mitoxantrone - therapeutic use
/ Molecular Docking Simulation
/ Mutation
/ Oncology
/ Proteins
This website uses cookies to ensure you get the best experience on our website.